Safety Assessment of tocotrienol supplementation in subjects with metabolic syndrome: A randomised control trial

Journal of Oil Palm Research

Volumn 28, Issue 1, 2016, Pages 34-43

  Lin, Gan Yee ^a   Ming, Lai Oi ^a   How, Chew Boon ^a   Hay, Yuen Kah ^b   Nesaretnam, Kalanithi ^c   Kim Tiu, Teng ^c   Selvaduray, Kanga Rani ^c   Meganathan, Puvanes Wari ^c   Yen, Fu Ju ^c  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b SCHOOL OF PHYSICS   (Malaysia)

^c MALAYSIAN PALM OIL BOARD   (Malaysia)

Author keywords

Metabolic syndrome; Safety; Tocotrienol; Vitamin E

Indexed keywords

EID: 84962338975     PISSN: 15112780     EISSN: None     Source Type: Journal    
DOI: 10.21894/jopr.2016.2801.05     Document Type: Article

References (44)

1. BJELAKOVIC, G; NIKOLOVA, D; GLUUD, L L; SIMONETTI, R G and GLUUD, C (2007). Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta analysis. JAMA Vol. 297 No. 8: 842-857.
2. BJELAKOVIC, G; NIKOLOVA, D; GLUUD, L L; SIMONETTI, R G and GLUUD, C (2012). Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst. Rev. 2012 No. 3 Art No. CD 007176.
3. BUDIN, S B; OTHMAN, F; LOUIS, S R; BAKAR, M A; DAS, S and MOHAMED, J (2009). The effects of palm oil tocotrienol-rich fraction supplementation on biochemical parameters, oxidative stress and the vascular wall of streptozotoxin-induced diabetic rats. Clinics (Sao Paulo) Vol. 63 No. 3: 235-244.
4. Clinical Practice Guideline (2009). Management of Type 2 D iabetes Mellitus. 4th edition. Ministry of Health, Malaysia.
5. DOWD, P and ZHENG, Z B (1995). On the mechanism of the anticlotting action of vitamin E quinone. Proc. Natl. Acad. Sci. USA. Vol. 92 No. 18. p. 8171-8175.
6. EFSA (2008). Opinion on mixed tocopherols, tocotrienol tocopherol and tocotrienols as sources for vitamin E added as a nutritional substance in food supplements. Scientific opinion of the scientific panel on food additives, flavourings, processing aids and materials in contact with food. (Question No. EFSA Q-2005-146, Q-2005-172, Q-2006-265.) EFSA J. Vol. 640: 1-34.
7. FABRY, S C and NARASIMHAN, R A (2007). 100 Questions & Answers about Hepatitis C: A Lahey Clinic Guide. Jones and Bartlett Learning Publishers: Sudbury, Massachusetts.
8. FAIRUS, S; NOR, R M; CHENG, H M and SUNDRAM, K (2006). Postprandial metabolic fate of tocotrienol-rich vitamin E differs significantly from that of alpha-tocopherol. Am. J. Clin. Nutr. Vol. 84 No. 4: 835-842.
9. FISCHBACH, F T and DUNING III, M B (2009). A Manual of Laboratory and Diagnostic Tests. 8th edition. Wolters Kluwer Health/Lippincott Williams & Wilkins: Philadelphia, USA.
10. GRUNDY, S M; CLEEMAN, J I; DANIELS, S R; DONATO, K A; ECKEL, R H; FRANKLIN, B A; GORDON, D J; KRAUSS, R M; SAVAGE, P J; SMITH, S C; SPERTUS, J A and COSTA, F (2005). Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation Vol. 112 No. 17: 2735-2752.
11. Haffner, s m (2006). The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am. J. Cardiol. Vol. 97 No. 2A: 3A-11A.
12. Heng, E C; Karsani, S A; ABDUL RAHMAN, M; ABDUL HAMID, N A; HAMID, Z and WAN NGAH, W Z (2013). Supplementation with tocotrienol-rich fraction alters the plasma levels of apolipoprotein A-I precursor, apolipoprotein E precursor, and C-reactive protein precursor from young and old individuals. Eur. J. Nutr. Vol. 52 No. 7: 1-10.
13. HUANG, P L (2009). A comprehensive definition for metabolic syndrome. Dis. Model Mech. Vol. 2 No. 5-6: 231-237.
14. IMA-NIRWANA, S and SUHANIZA, S (2004). Effects of tocopherols and tocotrienols on body composition and bone calcium content in adrenalectomized rats replaced with dexamethasone. J. Med. Food Vol. 7 No. 1: 45-51.
15. IMA-NIRWANA, S; NURSHAZWANI, Y; NAZRUN, A S; NORLIZA, M and NORAZLINA, M (2011). Subacute and subchronic toxicity studies of palm vitamin E in mice. J. Pharmocol. Toxicol. Vol. 6: 166-173.
16. Institute of Medicine (2000). Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium and Carotenoids. National Academy Press, Washington, DC.
17. KHALILI, H; DAYEH, B A and FRIEDMAN, L S (2011). Assessment of liver function in clinical practice. Chronic Liver Failure (Gines, P; Kamath, P S and Arroyo, V eds.). Humana Press, New York, USA. p. 47-76.
18. KHANNA, S; ROY, S; SLIVKA, A; CRAFT, T K; CHAKI, S; RINK, C; NOTESTINE, M A; DEVRIES, A C; PARINANDI, N L and SEN, C K (2005). Neuroprotective properties of the natural vitamin E α-tocotrienol. Stroke Vol. 36 No. 10: 2258-2264.
19. KLEIN, E A; THOMPSON, I M; TANGEN, C M; CROWLEY, J J; SCOTT LUCIA, M; GOODMAN, P J; MINASIAN, L M; FORD, L G; PARNES, H L; MICHEAL GAZIANO, J; KARP, D D; LIEBER, M M; WALTHER, P J; KLOTZ, L; PARSONS, J K; CHIN, J L; DARKE, A K; LIPPMAN, S M; GOODMAN, G E; MEYSKENS, F L and BAKER, L H (2011). Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). JAMA Vol. 306 No. 14: 1549-1556.
20. Lonn, E; Bosch, J; Yusuf, S; Sheridan, P; Pogue, J; Arnold, J M; Ross, C; Arnold, A; Sleight, P; Probstfield, J; DAGENAIS, G R and HOPE-TOO TRIAL INVESTIGATORS (2005). Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA Vol. 293 No. 11: 1338-1347.
21. Mahalingam, D; Radhakrishnan, A K; Amom, Z; Ibrahim, N and NesaretNam, K (2011). Effects of supplementation with tocotrienolrich fraction on immune response to tetanus toxoid immunization in normal healthy volunteers. Eur. J. Clin. Nutr. Vol. 65 No. 1: 63-69.
22. MILLER, E R; PASTOR-BARRIUSO, R; DALAL, D; RIEMERSMA, R A; APPEL, L J and GUALLAR, E (2005). Meta-analysis: high dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. Vol. 142 No. 1: 37-46.
23. MENSINK, R P; HOUWELINGEN, A C; KROMHOUT, D and HORNSTRA, G (1999). A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. Am. J. Clin. Nutr. Vol. 69 No. 2: 213-219.
24. NAKAMURA, H; FURUKAWA, F; NISHIKAWA, A; MIYAUCHI, M; SON H Y; IMAZAWA, T and HIROSE, M (2001). Oral toxicity of a tocotrienol preparation in rats. Food Chem. Toxicol. Vol. 39 No. 8: 799-805.
25. NESARETNAM, K; SELVADURAY, K R; ABDUL RAZAK, G; VEERASENAN, S D and GOMEZ, P A (2010). Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial. Breast Cancer Res. Vol. 12 No. 5: R81-R88.
26. NEWAZ, M A and NAWAL, N N (1999). Effect of gamma-tocotrienol on blood pressure, lipid peroxidation and total antioxidant status in spontaneously hypertensive rats (SHR). Clin. Exp. Hypertens. Vol. 21 No. 8: 1297-1313.
27. O'Byrne, D; Grundy, S; Packer, L; Devaraj, S; Baldenius, K; Hoppe, P P; Kraemer, K; Jialal, I and Traber, M G (2000). Studies of LDL oxidation following alpha-, gamma-, or delta-tocotrienyl acetate supplementation of hypercholesterolemic humans. Free Radic. Biol. Med. Vol. 29 No. 9: 834-845.
28. OO, S L; CHANG, P and CHAN, K E (1992). Toxicological and pharmacological studies on palm vitee. Nutr. Res. Vol. 12 Suppl. 1: S217-S222.
29. PATEL, V; RINK, C; GORDILLO, G M; KHANNA, S; GNYAWALI, U; ROY, S; SHNEKER, B; GANESH, K; PHILLIPS, G; MORE, J L; SARKAR, A; KIRKPATRICK, R; ELKHAMMAS, E A; KLATTE, E; MILLER, M; FIRSTENBERG, M S; CHIOCCA, E A; NESARETNAM, K and SEN, C K (2012). Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. J. Nutr. Vol. 142 No. 3: 513-519.
30. PENNOCK, J F; HEMMING, F W and KERR, J D (1964). A reassessment of tocopherol chemistry. Biochem. Biophys. Res. Commun. Vol 17 No. 5: 542-548.
31. QURESHI, A A; QURESHI, N; WRIGHT, J J; SHEN, Z; KRAMER, G; GAPOR, A; CHONG, Y H; DEWITT, G; ONG, A and PETERSON, D M (1991). Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee). Am. J. Clin. Nutr. Vol. 53(4 Suppl): 1021S-1026S.
32. Qureshi, A A; Bradlow, B A; Salser, W A and Brace, L D (1997). Novel tocotrienols of rice bran modulate cardiovascular disease risk parameters of hypercholesterolemic humans. J. Nutr. Biochem. Vol. 8 No. 5: 290-298.
33. QURESHI, A A; KARPEN, C W; QURESHI, N; PAPASIAN, C J; MORRISON, D C and FOLTS, J D (2011). Tocotrienols-induced inhibition of platelet thrombus formation and platelet aggregation in stenosed canine coronary arteries. Lipids Health Dis. Vol. 10 No. 1: 58-70.
34. RASOOL, A H; YUEN, K H; YUSOFF, K; WONG, A R and RAHMAN, A R (2006). Dose dependent elevation of plasma tocotrienol levels and its effect on arterial compliance, plasma total antioxidant status, and lipid profile in healthy humans supplemented with tocotrienol rich vitamin E. J. Nutr. Sci. Vitaminol. (Tokyo), Vol. 52 No. 6: 473-478.
35. RASOOL, A H; RAHMAN, A R; YUEN, K H and WONG, A R (2008). Arterial compliance and vitamin E blood levels with a self-emulsifying preparation of tocotrienol rich vitamin E. Arch. Pharm. Res., Vol. 31 No. 9: 1212-1217.
36. SCHAUSS, A G; ENDRES, J R and CLEWELL, A (2012). Safety of unsaturated vitamin E tocotrienols and their isomers. Tocotrienols: Vitamin E beyond Tocopherols (Tan, B; Watson, R R and Preedy, V R, eds.). AOCS Press: Urbana IL; Taylor & Francis/CRC Press: Boca Raton, FL. p. 17-35.
37. TAN, D T; KHOR, H T; LOW, W H; ALI, A and GAPOR, A (1991). Effect of a palm-oil-vitamin E concentrate on the serum and lipoprotein lipids in humans. Am. J. Clin. Nutr. Vol. 53 No. 4 Suppl.:1027S-1030S.
38. TASAKI, M; UMEMURA, T; INOUE, T; OKAMURA, T; KUROIWA, Y; ISHII, Y; MAEDA, M; HIROSE, M AND NISHIKAWA, A (2008). INDUCTION OF characteristic hepatocyte proliferative lesion with dietary exposure of Wistar Hannover rats to tocotrienol for 1 year. Toxicology Vol. 250 No. 2-3: 143-150.
39. Tomeo, A C; Geller, M; Watkins, T R; Gapor, A and Bierenbaum, M L (1995). Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Lipids Vol. 30 No. 12: 1179-1183.
40. WENG-YEW, W; POUDYAL, H; WARD, L C and BROWN, L (2012). Tocotrienols reverse cardiovascular, metabolic and liver changes in high carbohydrate, high fat diet-fed rats. Nutrients Vol. 4 No. 10: 1527-1541.
41. YAP, S P; YUEN, K H and WONG J W (2001). Pharmacokinetics and bioavailability of alpha-, gamma-and delta-tocotrienols under different food status. J. Pharm. Pharmacol. Vol.53 No. 1: 67-71.
42. YAP, S P and YUEN, K H (2004). Influence of lipolysis and droplet size on tocotrienol absorption from selfemulsifying formulations. Int. J. Pharm. Vol. 281 No. 1-2: 67-78.
43. Yuen, K H; Wong, J W; Lim, A B; Ng, B H and Choy, W P (2011). Effect of mixed-tocotrienols in hypercholesterolemic subjects. Functional Foods in Health and Disease Vol. 3: 106-117.
44. ZAIDEN, N; YAP, W N; ONG, S; XU, C H; TEO, V H; CHANG, C P; ZHANG, X W; NESARETNAM, K; SHIBA, S and YAP, Y L (2010). Gamma delta tocotrienols reduce hepatic triglyceride synthesis and VLDL secretion. J. Atheroscler. Thromb. Vol.17 No. 10: 1019-1032.